Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treatment of glutathione deficient mammals

a glutathione deficiency and mammals technology, applied in the field of mammals with glutathione deficiency, can solve the problems of affecting the inability to use cysteine normally being the rate-limiting factor, and the inability to achieve sustained gsh depletion, etc., to achieve the effect of stimulating the natural production of glutathion

Inactive Publication Date: 2009-07-14
VIT IMMUNE L C
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The composition significantly increases intracellular glutathione levels, improving immune response, liver function, and overall health by maximizing glutathione production and preservation, effectively addressing depleted glutathione-related conditions such as immunodeficiency and chronic diseases.

Problems solved by technology

First, cysteine and glutamate are combined (by the enzyme gamma-glutamyl cysteinyl synthetase, with availability of cysteine usually being the rate-limiting factor.
The consequences of sustained GSH depletion are fatal.
Then zones of tissue damage begin to appear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treatment of glutathione deficient mammals

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0053]A mixture of the following ingredients is prepared by hand mixing:

[0054]

IngredientQuantityN-acetylcysteine1,000 to 20,000mgvitamin C5,000 to 50,000mgalpha-lipoic acid100 to 2,500mgsylmarin100 to 2,500mgQuercetin100 to 2,500mgl-glutamine500 to 2,000mgN-acetyl-d-glucosamine500 to 2,000mgwhey protein concentrate1,000 to 20,000mgTwenty Million to One BillionCFU; Schiff Products, Inc.,Salt Lake City, Utah.orange essence flavorAdjust to taste

[0055]The mixture which constitutes the essential active ingredient of a preferred embodiment of the invention, together with a flavorant may be compounded into wafers, tablets or capsules containing 750 to 14,000 mg of active ingredient. In an uncompounded form, the powder dry mixture may be orally administered to a human (one teaspoonful, once or twice daily) as a dietary supplement or as recommended by a health care professional. Alternatively, the dry powder may be mixed with juice, water or food to facilitate administration.

example 2

[0056]Three dosage units in powder form, each containing 500 mg of essential active ingredient (e.g an amount of the mixture of Example 1, supra. were prepared from the following ingredients:

[0057]

essential active ingredient1500gstarch (Rx-1500)300gmagnesium stearate, USP39gcolloidal silicic acid19.5gAvicel ® pH 102. q.s. to3900g

[0058]The essential active ingredient was ground through a 0.25 mm sieve opening screen. The powdered active ingredient, with 50% of the total amount of magnesium stearate be used, colloidal silicic acid and Avicel® pH 10.2 were passed through a 40 mesh sieve, mixed for 20 minutes and then slugged. The slugs were broken down by forcing through a screen No. 11, and mixed with the remaining magnesium stearate.

[0059]One dosage given orally 1-4 times a day is useful in the relief of immuno-deficiency in adult humans provoked by infective disease, or other etiological causes.

example 3

[0060]Three thousand dosage units for oral use, each containing 750 mg of the essential active ingredient, were prepared from the following ingredients:

[0061]

essential active ingredient750gcolloidal silicic acid30gmagnesium stearate, USP30gmicrocrystalline cellulose150glactose90g

[0062]In accordance with the active ingredient potency, the amount of lactose was adjusted to achieve a weight of 900 mg for each dosage unit. The ingredients were passed through a 40 mesh sieve and mixed for 30 minutes. The powder may be mixed into a drink or inserted into hard gelatin capsules No. 0 and filled using Zanazi, model RV-59 equipment. The capsules should be preserved in airtight, light-resistant containers.

[0063]When administered to a human adult suffering from low levels of glutathione (GSH) 1 to 4 dosage units daily, the level is adjusted upward to a normal range.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
weightaaaaaaaaaa
compositionaaaaaaaaaa
Login to View More

Abstract

Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intracellulary either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels. The disclosure is also of a unique combination of nutritional supplements including n-acetyl cysteine, vitamin C, l-glucosamine, n-acetyl d-glucosamine, quercitin, sylimarin, Alpha lipoic acid and high protein, low fat whey that are combined to support various bodily systems involved in glutathione synthesis, reutilization and storage; all intended to elevate glutathione concentration in the mammalian cell.

Description

[0001]This application is a Continuation of Ser. No. 09 / 994,164, filed Nov. 26, 2001, now RE 39,705, which is a Reissue of Ser. No. 09 / 302,217, filed Apr. 29, 1999, now U.S. Pat. No. 6,262,019, which claims the benefit of Provisional Application No. 60 / 083,661 filed Apr. 30, 1998.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]This invention provides a method of improving glutathione (GSH) concentrations, both intra and extra-cellularly, in mammals, thereby improving the cellular and humoral immune response. It comprises oral administration of a therapeutically effective amount of nutritional supplement which is composed of critical and synergistic quantities of amino acids, peptides, and bioflavanoids.[0004]2. Brief Description of Related Art[0005]Glutathione is a well-known tripeptide, which exists in two basic forms. The antioxidant form or “reduced glutathione” tripeptide is conventionally called “glutathione” and abbreviated as “GSH”. The oxidized form is a sulf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A01N37/18A61K38/02A23L1/30A23L1/305A23L33/15A61K31/197A61K31/375A61K31/70
CPCA23V2002/00A61K31/197A61K31/375A61K31/70Y10S530/833A23L33/105A23L33/12A23L33/15A23L33/175A61K31/195A61K31/385A61K31/35A61K2300/00A23V2250/0616A23V2250/708A23V2250/026A23V2250/2116A23V2250/062A23V2250/54252A23V2250/206A23V2250/1866A23V2250/02A23V2250/032A23V2250/044A23V2250/51084A23V2250/5118A23V2250/1628A23V2250/161A23V2250/1886
Inventor KELLER, ROBERT H.KIRCHENBAUM, DAVID W.
Owner VIT IMMUNE L C
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com